Predicting distant metastasis and chemotherapy benefit in pediatric brain cancer

Not all pediatric patients can benefit from adjuvant chemotherapy, and particularly, some pediatric patients may even get worse outcomes after the treatment. The aim of our research is to develop and validate an MRI-based artificial intelligence model for the prediction of chemotherapy benefits within a multi-center dataset. The artificial intelligence model is to discriminate pediatric patients into the high and low risk of metastasis and identify potential candidates for therapy de-escalation and will be compared with the current clinical models.